Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Quarterly Earnings Results, Misses Expectations By $0.48 EPS

by · The Cerbat Gem

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.48), FiscalAI reports. The firm had revenue of $196.40 million for the quarter, compared to analyst estimates of $195.16 million. Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN traded up $2.61 on Tuesday, reaching $53.30. The stock had a trading volume of 2,134,794 shares, compared to its average volume of 726,747. The company has a market cap of $3.06 billion, a price-to-earnings ratio of -156.76, a P/E/G ratio of 0.64 and a beta of 0.71. Supernus Pharmaceuticals has a 12-month low of $29.16 and a 12-month high of $57.65. The firm’s fifty day moving average is $50.24 and its two-hundred day moving average is $48.01.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on SUPN shares. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Stifel Nicolaus raised their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Finally, Bank of America assumed coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They set a “buy” rating and a $65.00 target price on the stock. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $61.60.

Read Our Latest Research Report on Supernus Pharmaceuticals

Insider Buying and Selling

In other Supernus Pharmaceuticals news, Director Bethany Sensenig sold 4,475 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $51.01, for a total value of $228,269.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total value of $31,552.40. Following the sale, the vice president owned 14,508 shares in the company, valued at $644,735.52. This trade represents a 4.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 25,185 shares of company stock worth $1,268,022. 8.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SUPN. State Street Corp raised its stake in shares of Supernus Pharmaceuticals by 1.4% in the 4th quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock valued at $110,296,000 after acquiring an additional 31,668 shares during the period. Loomis Sayles & Co. L P raised its position in Supernus Pharmaceuticals by 12.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock valued at $72,007,000 after purchasing an additional 162,905 shares during the period. Woodline Partners LP lifted its stake in shares of Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after purchasing an additional 490,835 shares in the last quarter. Morgan Stanley boosted its position in shares of Supernus Pharmaceuticals by 42.9% in the fourth quarter. Morgan Stanley now owns 1,079,471 shares of the specialty pharmaceutical company’s stock worth $53,650,000 after buying an additional 324,154 shares during the period. Finally, Bank of America Corp DE grew its stake in shares of Supernus Pharmaceuticals by 67.1% in the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after buying an additional 338,584 shares in the last quarter.

About Supernus Pharmaceuticals

(Get Free Report)

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Further Reading